



**Poster Session 1**  
**12:30 – 2:00 p.m.**  
**Wednesday, December 11**

P1-01-01: Mainstream Cancer Genetics Testing in Primary Care at a Federally Qualified Health Center: Preliminary Findings from the TestMiGenes Study	Pamela Ganschow
P1-01-02: T cell mediated breast cancer protection following lactation and involution.	Sherene Loi
P1-01-03: Enhancing Patient Care: A Digital Approach Improves Universal Breast Cancer Risk Stratification in Imaging Centers	Jenna Cooke
P1-01-04: EPLIN and EPLIN responsive protein APOC3 in breast cancer	Cai Wang
P1-01-05: Conducting Ancillary Studies during an Active NCTN/NCORP Screening Trial – The TMIST (ECOG-ACRIN EA1151) Experience	Etta Pisano
P1-01-06: Whole-genome landscapes of 1,364 breast cancers with clinical outcomes	Ryul Kim
P1-01-07: Radiogenomics during neoadjuvant therapy with aromatase inhibitors: integrating dynamic magnetic resonance data and molecular biology	Stephanie Lee
P1-01-08: Chemoprevention Uptake Before and After the Release of Evidence-Based Guidelines for Low-Dose Tamoxifen Among Patients with Atypical Hyperplasia, Lobular or Ductal Carcinoma In Situ	Katherine Crew
P1-01-09: Clinicopathological features, treatment patterns and outcomes of germline BRCA mutation (gBRCAm)-associated breast cancer compared with sporadic tumors in young women: a matched analysis.	Stefania Morganti

P1-01-10: Comparison of different gene expression tests in breast cancer: poor correlation of Prosigna, EndoPredict and MammaPrint	Brigitte Schober
P1-01-11: Use of a Digital Navigator to Deliver Patient-Centered Genetic Services in Mammography	Tara Schmidlen
P1-01-12: Impact of Preoperative BRCA Testing and National Health Insurance Coverage on Surgical and Risk-reducing Decision-making in Japanese BRCA-mutated Breast Cancer Patients	Kumiko Kida
P1-01-14: Risk-reducing medications and primary breast cancer prevention: a network meta-analysis of randomized controlled trials.	Ghazaleh Pourali
P1-01-15: Assessing BRCA1/2 Testing in Breast Cancer Patients: A Retrospective Analysis of Real-World Data From the IntegraConnect PrecisionQ De-Identified Database	Fred Kudrik
P1-01-16: Molecular landscape of HR+/HER2- male breast cancer (MaBC) compared with female breast cancer (FeBC)	Dario Trapani
P1-01-17: PD-L1 Upregulation in Circulating Tumor Associated Cells Predicts for clinical outcomes in a phase I/II clinical trial using SV-BR-1-GM vaccine with the check point inhibitor retifanlimab in Metastatic Breast Cancer Patients, an Interim Analysis	Daniel Adams
P1-01-18: Prevalence of functional HRD by the RAD51 assay: a pooled analysis with 367 patients from BRCA-associated tumor types	Guillermo Villacampa
P1-01-19: Predicting response to capivasertib in AKT1 mutant advanced breast cancer	Alex Pearson
P1-01-20: Spliceosome Mutations (Smut) in Metastatic Breast Cancer (MBC): An Analysis of a De-centralized Clinical Trial and Large Clinical-Genomic Dataset	David Choi
P1-01-21: Clonal Hematopoiesis as a Driver of Metastasis Promoting Inflammation and Relapse in Breast Cancer	Pablo Sanchez Vela
P1-01-23: Oncotype DX Breast Recurrence Score® distribution and prognostic value according to prior pregnancy status in young women with breast cancer	Guilherme Nader-Marta

P1-01-24: Genomic comparison of rapid vs. typical progressors on CDK4/6 inhibitor treatment in advanced breast cancer	Katherine Clifton
P1-01-25: Elacestrant vs SOC in ER+, HER2- advanced or metastatic breast cancer (mBC) with ESR1-mutated tumors: ESR1 allelic frequencies and clinical activity from the phase 3 EMERALD trial	Aditya Bardia
P1-01-26 Genomic profiling of ctDNA and association with efficacy in patients from the postMONARCH trial of abemaciclib + fulvestrant vs placebo + fulvestrant for HR+, HER2-, advanced breast cancer following progression on a prior CDK4/6i plus endocrine therapy	Seth Wander
P1-01-27: HER2 Loss Following Treatment with Trastuzumab Deruxtecan in Patients with Metastatic Breast Cancer	Mohamed Gouda
P1-01-28: Molecular Residual Disease Precedes Radiographic Confirmation of Recurrence in Patients with Stage III Inflammatory Breast Cancer	Jennifer Chen
P1-01-29: Metabolomic signatures of fruit and vegetable consumption in relation to breast cancer	Emily Riseberg
P1-01-30: Generation and validation of primary breast cancer epigenetic classifiers of pathologic nodal stage in a multi-center breast cancer cohort	Miquel Ensenyat-Mendez
P1-02-01: Body weight modification during adjuvant ovarian suppression for premenopausal women with luminal breast cancer.	Izabela Porto ferreira
P1-02-02: Indirect comparison of sacituzumab govitecan (SG) and datopotamab deruxtecan (Dato-DXd) in advanced breast cancer (aBC): safety and efficacy analysis.	Neha Pathak
P1-02-03: Major adverse cardiovascular events in postmenopausal women vs pre-menopausal women with hormone receptor-positive breast cancer treated with endocrine therapy	Savannah Roy
P1-02-04: Impact of abemaciclib dose escalation on compliance and safety in hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer	Heather Moore
P1-02-05: The association between statin use and risk of cardiovascular events among breast cancer patients receiving pembrolizumab	Xiaocao "Haze" Xu

P1-02-06: Efficacy analysis & updated safety from the phase 2 PRIMED study of prophylactic granulocyte-colony stimulating factor (G-CSF) & loperamide for patients (pts) with HER2-negative advanced breast cancer (ABC) treated w/ sacituzumab govitecan (SG)	Elena Lopez
P1-02-07: Topical modulation of nociceptor epidermal terminals delays and ameliorates CIPN improving the quality of life of breast cancer patients	Sonia Servitja
P1-02-08: Incidence of cardiotoxicity in patients with breast cancer receiving human epidermal growth factor 2 (HER2) targeted monoclonal antibodies and antibody-drug conjugates: A Systematic review and meta-analysis.	Ilana Schlam
P1-02-09: Evolution of Breast Cancer Management after Hodgkin Lymphoma: Towards a breast- Conserving Approach	Jihane Bouziane
P1-02-10: Real-world analysis of interstitial lung disease in patients with HER2-positive unresectable or recurrent breast cancer treated with trastuzumab deruxtecan: all-patient post-marketing surveillance study in Japan	Junji Tsurutani
P1-02-12: Prospective phase II study on the efficacy and safety of hetrombopag for the treatment of cancer therapy-induced thrombocytopenia in patients with breast cancer	Hanfang Jiang
P1-02-13: Longitudinal analysis of cancer-related cognitive impairment in patients with luminal-like breast cancer undergoing chemotherapy and/or endocrine therapy - the Champalimaud-Helsinki study	Berta Sousa
P1-02-14: Rate of Fracture After Discontinuation of Bone Modifying Agents in Patients with Early-Stage Breast or Prostate Cancer on Hormonal Therapy	Mara Hofherr
P1-02-15: Natural history including the incidence, severity and management of diarrhea in patients with breast cancer receiving abemaciclib and pertuzumab-based therapies with or without standard chemotherapy: Data from placebo arm of the OnTarget study	Pablo Okhuysen
P1-02-16: Matched pair single-cell RNA-sequencing highlights the impact of abemaciclib and endocrine therapy on different myeloid cell populations in advanced ER+/HER2- breast cancer	Sarah Sammons
P1-02-17: Rediscovering Denosumab: Immunomodulation of the Tumor Microenvironment in Early-Stage Breast Cancer through RANK Pathway Inhibition	Andrea Vethencourt
P1-02-18: Cancer-Associated Fibroblast-Mediated Suppression of T Cell Activity as a mechanism of Resistance to Immunoradiotherapy in Breast Cancer	Rongrong Wu

P1-02-19: Spatially defining T-cell clonal evolution in post-neoadjuvant breast cancer and association with molecular residual disease.	Julia Ransohoff
P1-02-20: Visceral adiposity is associated with survival and distinct gene expression patterns in HER2-enriched subtype tumors	Elizabeth Cespedes Feliciano
P1-02-21: Dissecting the tumor immune microenvironment by single cell transcriptomics and immune repertoire analysis in breast tumors treated with the aromatase inhibitor letrozole and the CDK4/6 inhibitor ribociclib.	İlayda Altınönder
P1-02-22: The role of tumor-infiltrating lymphocytes (TILs) in the progression of human high-grade ductal carcinoma in situ (DCIS) to invasive breast carcinoma (IBC)	Hossein Schandiz
P1-02-23: Deciphering VISTA immunoreceptor mechanisms to target VISTA+ triple-negative breast cancers	Joshua Gruber
P1-02-24: Leveraging bulk and single-cell RNA sequencing to identify features predicting response and survival to abemaciclib in six mouse models of breast cancer.	Yash Agrawal
P1-02-25: New Murine Mammary Tumor Cell Lines for Syngeneic Studies Including Immunotherapy	Thomas Kalantzakos
P1-02-26: Biomarkers in metastatic breast cancer with brain metastases – a subanalysis of matched tumor samples of the BMBC registry	Elena Laackmann
P1-02-27: A novel 1st-in-class RAS/ $\beta$ -catenin inhibitor concurrently targets cancer cells and MDSC to reverse the immunosuppressive tumor microenvironment: antitumor activity in mouse models of breast and other cancers	Gary Piazza
P1-02-28: PDGFRa+/FAP- fibroblasts at multiplex in situ resolution are associated with resistance to HER2 blockade in neoadjuvant treated HER2+ breast cancer: results from the Swedish PREDIX HER2 trial	Georgios Manikis
P1-02-29: Targeting RANK pathway in combination with CDK4/6 inhibitors decreases the growth of palbociclib-resistant breast tumors via cancer cells and tumor microenvironment-mediated effects	Sandra Casimiro
P1-02-30: A Stromal Proteomic Investigation of the RAHBT Cohort: Collagen Molecular Patterns Link to Recurrence in Ductal Carcinoma in Situ	Taylor Hulahan

P1-03-01: Towards Universal Germline Screening for Breast Cancer, Planning for a Sustainable Future: A Single-Center Retrospective Analysis	Adela Rodriguez Hernandez
P1-03-02: Unveiling Genetic Predispositions: Germline Genetic Testing in Arab Male Breast Cancer Patients	Faris Tamimi
P1-03-03: Impact of Mainstreaming Protocol in Clinical Practice of Breast Cancer Patients	João Araújo
P1-03-04: Breast cancer related lymphedema rates following sentinel lymph node biopsy: how concerned should patients and clinicians be?	Lyndsey Kilgore
P1-03-05: RNA-sequencing data in diverse women diagnosed with ductal carcinoma in situ	Aditi Hazra
P1-03-06: Abrupt Involution Leads to Long-Term Mitochondrial Dysfunction and Metabolic Shift – Increasing Risk of Breast Cancer	Kate Ormiston
P1-03-07: Identifying risk factors for Benign Breast Disease in Donors to the Komen Tissue Bank	Rina Yadav
P1-03-08: Clinico-pathological Characteristics of Breast Invasive Lobular Carcinoma in non-CDH1 genetic predisposition. Experience from the Institut Curie.	Lounes Djerroudi
P1-03-09: Predicted Probability of Germline Genetic Testing and Counseling of Breast Cancer Patients in Eastern North Carolina	Joshua Zweigle
P1-03-10: Prevalence of BRCA mutations in patients with HER2-negative breast cancer and high-grade serous ovary in the Dominican Republic.	Rosa Vassallo
P1-03-11: Unique double BRCA2 mutations c.2254_2257del/c.5351dup in Patients with Breast Cancer from Jordan	Faris Tamimi
P1-03-12: Reprogramming SREBP1-dependent metabolism and inflammation in high-risk breast to prevent cancer: the example of licochalcone A	Atieh Hajirahimkhan

P1-03-13	Open
P1-03-14: Lympho-Vascularized Breast-Skin Platform for Modeling Lymphovascular Space Invasion in Advanced Breast Cancer	Melika Mehrabi-Dehdezi
P1-03-15: Characterization of metabolic and energetic risk factors and preventative breast surgical decisions in a cross-sectional survey cohort of hereditary cancer pathogenic variant carriers	Lauren Nye
P1-03-16: Multimodal analyses of clinical, radiology, pathology and genomic information for enhanced prediction of response to neoadjuvant therapy in breast cancer	Sarah Eskreis-Winkler
P1-03-17: Disseminated tumor cell (DTC) quantities are associated with Ki67 and pCR rate in breast cancer	Laura Weydandt
P1-03-18: Correlates of Breast Adipose Inflammation after Primary Breast Cancer Diagnosis in the Pathways Study	Lawrence Kushi
P1-03-19: Comprehensive Analysis of ADC Target Expression in Invasive Lobular Carcinoma	Jason Mouabbi
P1-03-20: Role of MCM2 and the licensing complex in predicting endocrine and CDK4/6 inhibitor resistance in ER+ breast cancer	Alekya Raghavan
P1-03-21: Improving gene signatures for predicting the progression of ductal carcinoma in situ	Diego Marzese
P1-03-22: Comprehensive characterization of the androgen receptor in male breast cancer	Priya Jayachandran
P1-03-23: Identification of Stage 1 Breast Cancer Biomarkers Using Extracellular Vesicle Proteomics and Machine Learning	Todd Hembrough
P1-03-24: Genomic and Clinicopathologic Profiling of Breast Invasive Lobular Carcinoma in Patients with Germline Predisposition	Christopher Schwartz

P1-03-25: Characterization of the tumor immune microenvironment (TIME) and somatic landscape of metaplastic breast cancer (MpBC)	Shaveta Vinayak
P1-03-26: Genomic Landscape of primary vs secondary Endocrine Resistance in HR+/HER2- advanced breast cancer: the GLIDER study	Grazia Castellano
P1-03-27: Circulating tumor DNA (ctDNA) dynamics as a predictor of treatment response: a review of Liquid Biopsy-RECIST (LB-RECIST) criteria in Metastatic Breast Cancer (MBC)	LORENZO FOFFANO
P1-03-28: Agreement between the DESTINY-Breast04/06 VENTANA 4B5 HER2 IHC clinical trial assay and other comparator assays for HER2-low breast cancer: Overall results of a large-scale, multicenter global ring study	Giuseppe Viale
P1-03-29: Targeted Human Plasma Metabolomics for Lobular Breast Cancer Biomarker Discovery	Jean-Francois Haince
P1-03-30: Genomic risk score distribution and outcomes of patients with early-stage breast cancer diagnosed during pregnancy	Guilherme Nader-Marta
P1-04-01: Impact of Obesity, Skeletal Muscle Index, and Comorbidities on Chemotherapy-Related Outcomes in Early Breast Cancer: A Retrospective Subanalysis	Jasmin Hundal
P1-04-02: Longitudinal multi-omics study reveals potential targets against chemotherapy induced peripheral neuropathy during taxane treatment	Anukriti Sharma
P1-04-03: Model-predicted Neurokinin-1 (NK1) Receptor Occupancy of Netupitant versus Aprepitant Over an Extended Time Period: Implications for Controlling Nausea and Vomiting Associated with Antibody-Drug Conjugates (ADCs)	Matti Apro
P1-04-04: development and validation of a nomogram for axillary lymph node metastasis risk in breast cancer	Xiaoyun Mao
P1-04-05: Stroke-Related Mortality Trends Among Breast Cancer Patients in the United States from 1999 to 2020: A Retrospective Analysis	Moazzam Shahzad
P1-04-06: Reasons for Cannabis Use and Perceptions in Breast Cancer Patients Compared to Other Cancer Patients	Cristina Truica, Jeremy Ireland



P1-04-07: Incidence and Risk Factors of Immune-Related Adverse Events in Metastatic Breast Cancer Patients: Findings from a Multi-Institutional Study	Nikita Baclig
P1-04-08: Feasibility Evaluation and Implementation of a Digital Health Intervention (DHI) Mobile Health (mHealth) Electronic Patient-Reported Outcome Measure (ePROM) Based Platform for Telemonitoring Patients with Breast Cancer Undergoing Chemotherapy	Alessandra Morelle
P1-04-09: Evaluating the Necessity and Impact of Cardiac Imaging on Breast Cancer Care in Northwestern Ontario	Hannah Shortreed
P1-04-10: Peripheral blood cells as predictors of immune-related toxicity in early triple negative breast cancer (eTNBC)	Benedetta Conte
P1-04-11: Examining the risk factors for trastuzumab related cardiotoxicity in a predominantly Hispanic South Texas population: a descriptive study	Zuha Alam
P1-04-12: Optimizing Tolerability of Pyrotinib in HER2-Positive Early-Stage High-Risk Breast Cancer: A Multicenter, Randomized, Three-Cohort Study	Qiao Cheng
P1-04-13: Comparison of Time-to-Pregnancy in Young Breast Cancer Survivors versus the general population: a Prospective Case-Control Study (FEERIC) from a collaborative research network	Anne-Sophie HAMY
P1-04-14: Vaginal oestradiol pessaries for the treatment of genitourinary symptoms in women with early breast cancer: a single arm phase 2 study (OVGUS)	Antonia Pearson
P1-04-15: Real-World Analysis of Safety and Efficacy of Metastatic Breast Cancer Patients Receiving Capivasertib	Mara Hofherr
P1-04-16: Racial Disparities in the Pro-Metastatic Tumor Microenvironment of Treatment-Naive Breast Cancer	Burcu Karadal-Ferrena
P1-04-17: Exosomes as drivers and biomarkers of TAM recruitment and immune evasion in inflammatory breast cancer	Serena Lucotti
P1-04-18: Mediator Subunit 1 (MED1) and tumor-secreted small extracellular vesicles (sEV) in breast cancer immune evasion and progression	Mahendra Jadhao

P1-04-19: Regulating Stress to Improve Antitumor Immunity in Breast Cancer Models.	Gilberto (Gil) Gastelum Martinez
P1-04-20: Difference in transcriptional expression and immune infiltration analysis between recurrent and de novo stage IV HER2-negative breast cancer in the NEWBEAT trial; WJOG9917BTR.	Yukinori Ozaki
P1-04-21: Suppressing suppression: histone deacetylase inhibition primes the metastatic tumor microenvironment to respond to checkpoint inhibition by dynamic rewiring of cell interactions	Evanthia Roussos Torres
P1-04-22: Loss of SMAD4 Drives Breast Cancer Invasion and Metastasis through E2F1-Mediated Activation of the PEG10-ERK Axis	Dan Shu
P1-04-23: Subpopulations of tumor-infiltrating lymphocytes features in ER-low breast cancer	Maxim Khoroshilov
P1-04-24: Prognostic Value of Stromal Markers in Triple-Negative Breast Cancer: A Digital Image Analysis Approach	Zsófia Karancsi
P1-04-25: Fast and accurate detection of tumor-immune cell interactions with deep learning	Huiping Liu
P1-04-26: THE USE OF IMMUNE CELL HEATMAPS IN UNRAVELLING THE TUMOR MICROENVIRONMENT IN INFLAMMATORY BREAST CANCER.	Christophe Van Berckelaer
P1-04-27: Characterizing Tumor-Infiltrating Lymphocytes and Their Clinicopathological and Prognostic Significance in Triple-Negative Breast Cancer: an Analysis Focusing on Natural Killer Cells and Spatial Distribution	Eunkyung Han
P1-04-28: Comparison of tumor immune microenvironment of TNBC with different treatment outcome with neoadjuvant chemotherapy: Spatial analysis using multiplex fluorescent immunohistochemistry	Jee Hung Kim
P1-04-29: The expression patterns of the immune checkpoint molecules PD-1 and PD-L1 in the context of seroma development in breast cancer	Nina Ditsch
P1-04-30: Tumor-infiltrating lymphocytes around ductal carcinoma in situ on core needle biopsy can aid in the prediction of the presence of invasive carcinoma	Sawaka Yukishige

P1-05-01: Direct-to-Consumer “23andMe” Testing for Germline BRCA1 and BRCA2 Gene Variants among Arab Jordanians	Faris Tamimi
P1-05-02: Medium chain fatty acids shift metabolism towards the de novo serine pathway fostering epigenetic plasticity and oxidative DNA damage	Mariana Bustamante Eduardo
P1-05-03: Serum and breast tissue biomarker changes induced by Atorvastatin in women at increased risk for breast cancer	Amanda Lanier
P1-05-04: Two years of experience of the first broad breast cancer program in Nuevo León, México	Dione Aguilar
P1-05-05: Genetic profile of pathogenic variants associated with breast cancer identified in a Chilean inherited family oncological program	Karin Alvarez
P1-05-06: The frequency of somatic mutations in the PIK3CA gene in Kazakhstani patients with metastatic HR+ HER2-negative breast cancer.	Mariya Dmitrenko
P1-05-07: Expression of ATP6AP2 in clinical breast cancer and the prognostic and therapeutic value in ERBB2 subtype of breast cancer	Jia Tong
P1-05-08: Germline Mutations in Early Triple-Negative Breast Cancer Brazilian Patients	Giulia Zanetta
P1-05-09: High prevalence of germline BRCA1/2 pathogenic variants in TNBC patients who achieve pCR: results from the TRINITY study.	Emmanouil Saloustros
P1-05-10: Investigating the Potential Role of Rare Germline Non-Coding Variants in Cancer Predisposition Genes in Patients with Triple-Negative Breast	Michela Palleschi
P1-05-11: The timing of BRCA1/2 germline testing and patient’s decision toward the risk-reducing mastectomy in breast cancer	Eunhye Kang
P1-05-12: The 70-Gene Signature Assay vs. Traditional Clinical Risk Assessment: Impact on Adjuvant Chemotherapy Choices in Mexican Breast Cancer Patients	Diego Ontiveros Ramírez

P1-05-13: Rates of Adherence to NCCN Breast Cancer Screening Recommendations among Unaffected Women with a Hereditary Breast Cancer Predisposition	Phuong Mai
P1-05-14: OnTarget crofelemer diarrhea prophylaxis trial: responder analysis of patients with breast cancer receiving targeted therapy with or without chemotherapy	Pablo Okhuysen
P1-05-15: A real-world analysis of cancer prevention measures among individuals with hereditary breast and ovarian cancer (HBOC) syndromes and no personal history of malignancy.	Abby Hadley
P1-05-16: Differential ctDNA-based genomic features of Triple-Negative Metastatic Lobular Breast carcinoma: insights into a rare and poorly understood disease	Lorenzo Gerratana
P1-05-17: Structural Variants Affecting CDH1 in Breast Invasive Lobular Carcinoma	Fresia Pareja
P1-05-18: Genomic Landscape in Advanced Breast Cancer Across Different Genomic Ancestries	Alejandro Rios Hoyo
P1-05-19: Circulating Tumor DNA as a Prognostic Biomarker for CDK 4/6 Inhibitor Therapy in Metastatic Breast Cancer	Luis China
P1-05-20: Validation of the HER2 Activation Response Predictive Signature (HARPS) as a Predictive Biomarker for HER2+ Therapy Response in the Neoadjuvant Setting	Emanuel Petricoin
P1-05-21: Prognostic implications of oncogenetic pathway alterations in advanced male breast cancer	Dario Trapani
P1-05-22: Targeting human Endoplasmic reticulum oxidoreductin 1-L $\alpha$ in novel therapy for triple negative breast cancer.	Asaka Wada
P1-05-23: An observational cohort study of Multiplex8+: a spatially informed assay that uses multiplexed RNA-FISH guided laser capture microdissection followed by total RNA-sequencing	Evan Paul
P1-05-24: Biomarkers and Spatial Determinants of SHR-A1811 Efficacy in Neoadjuvant Treatment for HER2-Positive Breast Cancer	Zhi-Ming Shao

P1-05-25: Improving the Specificity and Sensitivity of Digital 3D Mammography using serum, plasma and saliva derived proteomes and mathematical modeling	Kurayi Mahachi
P1-05-26: MammaPrint Genomic Signature, Molecular Subtype Characteristics and Outcomes of HER2-Low Early Breast Cancer (EORTC10041 / BIG 03-04 MINDACT Trial)	Gustavo Werutsky
P1-05-27: Analytical comparison of tissue-based next-generation sequencing assays for the detection of PIK3CA, AKT1, and PTEN tumor alterations in breast cancer	Xiaodun Li
P1-05-28: Immune related adverse events are associated with better event free survival in a Phase I/II Clinical Trial of Durvalumab Concomitant with Neoadjuvant Chemotherapy in Early-Stage TNBC	Alejandro Rios Hoyo
P1-05-29: The Nanomechanical Phenotype of Lobular Breast Cancer	Marko Loparic
P1-05-30: A statistical model for integration of on-treatment circulating tumor DNA dynamics and prediction of outcomes in patients with ER+/HER2- metastatic breast cancer	Mitchell Elliott
P1-06-01: Efficacy and Safety of Camrelizumab Combination Therapy in Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis	Moazzam Shahzad
P1-06-02: Remote functional cognitive rehabilitation in Breast Cancer Patients, a single center retrospective study	Einav Nili Gal-Yam
P1-06-03: Open	
P1-06-04: Psychological stress and its correlations to patients with acute lymphedema after breast cancer surgery	Li-Chen Tang
P1-06-05: Efficacy of using "cold caps" or "scalp cooling systems" with the DigniCap system in Uruguayan patients receiving chemotherapy for the treatment of early-stage breast cancer (Digni-T-Uy: DigniCap Trial Uruguay)	Dahiana Amarillo
P1-06-06: Oral cyclophosphamide-induced hemorrhagic cystitis from metronomic Cyclophosphamide/Methotrexate/5-Fluorouracil for treatment of synchronous bilateral breast cancer – A case report	Jina Yun

P1-06-07: APOE4 impairs the cardiac stress response to doxorubicin through defective M2 macrophage activation and tissue repair transcription pathways	Guannan Wang
P1-06-08: Quantifying Treatment Tolerability in Real-world Breast Cancer Practice: A Pragmatic Approach Utilizing Patient-Reported Outcomes (PROs)	Emelly Rusli
P1-06-09: Importance of Assessing Thyroid Dysfunction in Breast Cancer Patients Undergoing Pembrolizumab-based Neoadjuvant Chemotherapy	byeongju kang
P1-06-10: Long-term Cardiovascular Risks in Breast Cancer Survivors with Diabetes	Sixten Harborg
P1-06-11: Intravenous Iron in Early-Stage Breast Cancer Patients Receiving Neoadjuvant Chemotherapy	Jules Cohen
P1-06-12: Efficacy and safety of the addition of prophylactic atropine to patients with metastatic triple-negative breast cancer treated with sacituzumab govitecan: a Spanish multicenter real-world study	María José Echarri
P1-06-13: Financial Toxicity and Quality of Life in Breast Cancer Patients at a Safety Net Hospital	Bayle Smith-Salzberg
P1-06-14: The relevance of carbon footprint in enviro-logistical analysis in breast cancer trials	Stefan Lukac
P1-06-15: Multi-Site Real World Data of Patient Reported Outcomes from Patients with Breast Cancer on Immunotherapy or Antibody Drug Conjugates using the Carevive PROMPT™ Web-Based Platform	Kim Blenman
P1-06-16: Tumor Immune Micro-Environment (TIME) Effect of Cryoablation in Triple-Negative Breast Cancer - It was the best of TIMES...	Flavia Sardela de Miranda
P1-06-17: Inhibition of oncogenic PTK6 kinase enhances immune response against triple negative breast cancer via EMT reversal	Hanna Irie
P1-06-18: Variation of CCR7 Immune Cell Receptor Expression by Nodal Burden in Patients with Invasive Breast Cancer	Jennifer Chen

P1-06-19: Circulating Cytokine Profiles Associated with Differential Stromal Tumor Infiltrating Lymphocyte (sTIL) Levels in ER-positive Early Breast Cancer	Francisco Ayala de la Peña
P1-06-20: Gold Nanoparticle (AuNP) enhances therapeutic response to Radio–Immunotherapy Combination in Triple Negative Breast Cancer (TNBC)	Branislava Janic
P1-06-21: The Ral GTPases regulate the TNBC secretome to drive growth and metastasis.	Jonathan Spehar
P1-06-22: Challenging the paradigm for NK cell activation	Isabella Terrazas
P1-06-23: Extracellular matrix in Young Onset Breast Cancer – A dynamic niche as a therapeutic target	Lohita Krishna Kanyadhara
P1-06-24: Single-cell RNA sequencing reveals the role of HSPA1B+ immune cells in breast cancer microenvironment remodeling during neoadjuvant chemotherapy	Zihan Zhai
P1-06-25: B7-H3 (CD276): A Metabolic Switch for the Survival of Breast Cancer Brain Metastasis	Asad Rehman
P1-06-26: The optimal cut-off point for Tumor-Infiltrating Lymphocytes (TILs) in Triple-Negative Breast Cancer (TNBC)	Petr Krivorotko
P1-06-27: Role of MARCKS in regulating the tumor microenvironment in inflammatory breast cancer	Maroua Manai
P1-06-28: Assessment of the immune microenvironment of the breast cancer PAM50 Subtypes – a deconvolution approach	Lilly Anne Torland
P1-06-29: Targeting NRP1 reduces triple-negative breast cancer lung metastasis and improves immunotherapy efficacy	Zhuxi Duan
P1-06-30: Use of decellularized tumor and adipose tissue to model triple negative breast cancer	Marcus Moody

P1-07-01: The Semi-Dry Dot-Blot Kit Can Detect Lymph Node Metastases in Breast Cancer Regardless of Neoadjuvant Chemotherapeutic Effects	Yuki Hara
P1-07-02: Alteration of HER2 status following neoadjuvant chemotherapy in breast cancer: a clinicopathological analysis focusing on HER2-low status	Hyun-Jung Sung
P1-07-03: Improved Standardization and Accuracy of HER2 Score with AI support in Breast Cancer: Large Multicenter Study	Savitri Krishnamurthy
P1-07-04: Re-evaluation of a novel diagnostic kit which uses the semi-dry dot-blot method combined with an automatic reader to detect breast cancer metastases in sentinel lymph nodes: A multi-center prospective study	Ryota Otsubo
P1-07-05: Association of BMI variations with response to neoadjuvant chemoimmunotherapy for early-stage triple-negative breast cancer	Bethania Santos
P1-07-06: Adjunctive statistical standardization of quantitated adjuvant HER2 and very low statistically standardized HER2 in CCTG MA.27	Judith-Anne Chapman
P1-07-07: Secretory Carcinoma: Clinical, Pathological and Molecular Insights into a Rare Breast Cancer Subtype	Andrea Vethencourt
P1-07-08: LUMINAL BREAST CANCER HER 2 AMPLIFIED IS A DIFFERENT ENTITY THAN LUMINAL HER2(3+) LUHER2/3 STUDY	RONALD LIMON
P1-07-09: Development and validation of Residual tumor Burden calculator specific for Inflammatory breast carcinoma (IBC) to predict outcome (R-IBC)	Savitri Krishnamurthy
P1-07-10: Clinicopathologic Characterization of Hormone-Receptor Positive, HER2 Null, Ultralow, and Low Breast Carcinoma in the Metastatic Setting	Raza Hoda
P1-07-11: Evaluating the Correlation Between FISH and NGS in Assessing ERBB2 Alterations in Breast Cancer	Nikita Kotlov
P1-07-12: Comprehensive characterization of invasive mammary carcinoma with lobular features: Integrating morphology and E-cadherin immunochemistry pattern	Aeree Kim



P1-07-13: Adipocyte size in relation to clinical factors, mammographic density and quantitative histologic metrics in ductal carcinoma in situ (DCIS).	Charlotta Mulder
P1-07-14: MutL loss in ER+ breast cancer promotes pro-tumorigenic macrophage polarization that aids migration capacity	Megha Raghunathan
P1-07-15: Tumor size reduction and overall survival improvement in HER2-overexpressing cancer patients vaccinated with HER-Vaxx, a B-cell peptide-based vaccine, plus standard-of-care chemotherapy	Joshua Tobias
P1-07-16: Real-World Duration of Sacituzumab Govitecan-hziy Treatment in Patients with Metastatic Triple-Negative Breast Cancer	Fred Kudrik
P1-07-17: Mitotically-associated long noncoding RNA (MANCR): A novel long noncoding RNA that promotes genomic stability and cellular proliferation in Triple Negative Breast Cancer	Peter Kaufman
P1-07-18: Testing the Rac/Cdc42 inhibitor MBQ-167 in ex vivo cultures of Hispanic TNBC tissue	Anamaris Torres-Sanchez
P1-07-19: Old Medicine, New Application: Therapeutic Potential of the Second-Generation Antihistamine Aeriuss as a N-WASP Inhibitor in Breast Cancer Metastasis	Rhiannon Yannan Yu
P1-07-20: Mechanism of miR-221-3p/PARP1 regulating the progression of triple-negative breast cancer through the NF-κB pathway	Qianqian Lei
P1-07-21: Efficacy of CDK4/6 Inhibitor Abemaciclib in Metastatic Triple-Negative Breast Cancer	Chuling Zhuang
P1-07-22: Phase I Study of B7-H3 Specific Chimeric Antigen Receptor (CAR) T Cell Therapy in Patients with Triple-Negative Breast Cancer	Yara Abdou
P1-07-23: Matrix Metalloproteinase-7 regulates the process of pulmonary metastasis in triple-negative breast cancer cells	Ji Su Kim
P1-07-24: Induced Electric Fields Restrict Breast Cancer progression and metastasis via Immune Microenvironment Regulation	Manish Charan

P1-07-25: E3 ubiquitin-protein ligase RNF40 promotes triple-negative breast cancer progression and metastasis by promoting TRIM28 expression and stabilizing TWIST1 protein	Junjiang Fu
P1-07-26: Annexin A6 modulates the secretion of pro-inflammatory cytokines and exosomes via membrane fusion with SNAP 23 in triple negative breast cancer	Nobelle Sakwe
P1-07-27: Triple-negative breast cancer with bone marrow involvement and response after use of antibody-drug conjugate (ADC)	Sophia Freitas
P1-07-28: Real-World Study on Efficacy and Safety of SG Alone and Combined with Immunotherapy in Metastatic Triple Negative Breast Cancer Patients	Jianli Zhao
P1-07-29: Single cell RNA sequencing of triple negative breast cancer patient-derived xenograft model identifies AK1 as a key regulator of breast cancer metastasis	Woohang Heo
P1-07-30: Phase II adaptive TONIC2 trial to dissect immunomodulatory capacity of doxorubicin or cisplatin induction followed by anti-PD1 in mTNBC	Marleen Kok
P1-08-01: Aligning of cancer-associated collagens inhibits metastasis	Girdhari Rijal
P1-08-02: HIF-1-dependent expression of integrin $\beta$ 3 incorporated into extracellular vesicles promotes metastasis of breast cancer cells to the brain	Yongkang Yang
P1-08-03: Clinical Distribution and Impact of Biomarker Triads Consisting of either Quantified HER2 or EGF Receptor with ER and PR Proteins and Expression of Their Cognate Genes	Michael Daniels
P1-08-04: Efficiency of Low-Viscosity Culture for TNBC Organoid Establishment and Drug Screens	Xavier Bittman-Soto
P1-08-05: The mechanism of FOXO3a in coping with oxidative stress to promote TNBC progression	Manqing Cao
P1-08-06: Real-world outcomes and care utilization related to pregnancy in hormone receptor-positive breast cancer survivors	Julia Ransohoff

P1-08-07: Time Interval Between Diagnosis and Treatment of Early Breast Cancer and the Impact of Health Insurance Coverage in Latin America: A Sub Analysis of the LATINA Breast Study (LACOG 0615 / MO39485)	Gustavo Werutsky
P1-08-08: Real-world efficacy of immediate subsequent lines of therapy after trastuzumab deruxtecan (T-DXd) in patients with metastatic breast cancer (MBC) – retrospective study from the nationwide Flatiron database	Paolo Tarantino
P1-08-09: REAL-WORLD OUTCOMES COMPARING 3-MONTHLY WITH MONTHLY GOSERELIN IMPLANT IN PREMENOPAUSAL WOMEN WITH BREAST CANCER	Kelly E. McCann
P1-08-10: Germline BRCA1 and BRCA2 testing, Genetic Counseling and Adjuvant Therapy Patterns in Early Breast Cancer Patients	Monica Izano
P1-08-11: Incidence and Factors Predicting Survival in Inflammatory Breast Cancer: An Updated SEER Analysis	Malak Alharbi
P1-08-12: Clinical characteristics and survival outcome of patients with early discontinuation of first-line (1L) cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) therapy for HR+/HER2- advanced breast cancer: a nationwide, real-world study	Martina Pagliuca
P1-08-13: 1000 Patient Prospective Inflammatory Breast Cancer (IBC) Registry Demonstrates Advances in Outcomes for IBC.	Azadeh Nasrazadani
P1-08-14: The occurrence of immune-related adverse events and overall survival among breast cancer patients receiving pembrolizumab	Cho-Han Chiang
P1-08-15: Real-world analysis of breast cancer patients qualifying for adjuvant CDK4/6 inhibitors	Yada Kanjanapan
P1-08-16: Resolution of Active Pyoderma Gangrenosum during Adjuvant Breast Cancer Therapy: A Case Report	Abigail Lauder
P1-08-17: Successful Treatment of Early Triple-Negative Breast Cancer with Chemotherapy and Immune Checkpoint Inhibitor in the Setting of Sickle Cell Disease: a Case Report	Stevany Saxon-Filipe
P1-08-19: Surgical oncoplastic treatment of a rare case of expansive dermatofibrosarcoma protuberans on the breast	Giovanna Azevedo Gabriele Carlos

P1-08-20: Synchronic invasive lobular breast carcinoma, invasive mammary carcinoma NST, and large cell neuroendocrine carcinoma of the lung.	Leonardo Gil-Santana
P1-08-21: Synchronous female breast cancer and follicular lymphoma in a single patient: A case report	Zijun Zhao
P1-08-22: Open	
P1-08-23: Targeting Brain Metastasis: The Success of Trastuzumab-Deruxtecan in HER2+ Cancers: A Case Report	Annelies Feyaerts
P1-08-24: The diagnosis of Anti-Yo antibody mediated paraneoplastic syndrome, a rare neurodegenerative disorder in a patient with invasive breast cancer, a case report	Ashley Montgomery
P1-08-25: The differential diagnosis of a large breast mass in a young woman	Hetal Mistry
P1-08-26: Triple negative breast cancer in pregnant women with mutated BRCA	Leonardo Gil-Santana
P1-08-27: Unusual Presentation Of Triple-Negative Breast Cancer (TNBC) In A Young Female Patient With Xeroderma pigmentosum (XP)	Bashaer Alsaati
P1-08-28: Unusual Presentation of Metastatic Breast Cancer Mimicking Myelofibrosis	Emily Sargent
P1-08-29: Utility of 18F-FES PET/CT over 18F-FDG PET/CT in Initial Diagnosis of over Ninety Metastatic Lesions in a Patient with Metastatic ER+ Breast Cancer: A Case Report	Caroline Breit
P1-08-30: Vitiligo-like reaction in a patient with metastatic RH+/HER2-negative breast cancer treated with ribociclib: A case report and literature review	Anezka Ferrari
P1-09-01: Combination of tumor-infiltrating lymphocytes (TILS) and tumor-stroma ratio (TSR) in breast cancer: utility to guide clinical treatment of breast cancer	Fiorita Mundim

P1-09-02: Discordance in breast cancer pathology review and its impact on patient care	Ana Carolina Teixeira Pires
P1-09-03: An integrated genomic analysis of DCIS heterogeneity to identify signatures of progression and determine the clinical utility of ctDNA.	Philip Elliott
P1-09-04: A Phase II study of the efficacy and safety of Perflubutane for Predicting highly Tumor Infiltrating Lymphocytes in early breast cancer	Yuri Kimura
P1-09-05: Simultaneous 3D Mapping of RNA and Protein to Advance Personalized Medicine in Breast Cancer	Yue Li
P1-09-06: Evaluation of proliferation biomarker serum thymidine kinase activity and prediction of early relapse in HR positive HER2 negative high risk early breast cancer: Analysis from the PENELOPE-B trial	Amy Williams
P1-09-07: Retrospective study evaluating the characteristics of patients (pts) with early-stage estrogen receptor-positive (ER+) HER2- breast cancer (EBC) who relapsed on or after adjuvant (adj) abemaciclib (abema)	Chiara Corti
P1-09-08: A new modified technique "Modus Spiridonov 1" in fine-needle aspiration biopsy	Slavyana Usheva
P1-09-09: Disparities in Second Breast Cancer Events and Survival Persist Despite Optimal Treatment in Hormone-Receptor Positive Breast Cancer: Analysis of the Real-World ASCO CancerLinQ Dataset	Olga Kantor
P1-09-11: Machine Learning based analysis in chemotherapy resistant triple negative breast cancer	Dongling Wu
P1-09-12: Comparative Analysis of the Oncotype DX Breast Recurrence Score® assay for Neoadjuvant Letrozole/Abemaciclib versus Chemotherapy in Stage II-III, Ki67≥20%, HR+/HER2- Breast Cancer: Insights from the GEICAM/CARABELA Trial	Angel Guerrero-Zotano
P1-09-13: An Adjusted Breast Cancer Index Model to Identify Women with Hormone Receptor-Positive (HR+) Breast Cancer at Minimal Risk of 10-year Distant Recurrence (DR)	Marie-France Jilderda
P1-09-14: Palbociclib and endocrine therapy diminishes adaptive anti-tumor immunity	Michael Ignatiadis

P1-09-16: A Phase I Study of ASTX727 plus Talazoparib in Patients with Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer and non-mutated BRCA	Kathy Miller
P1-09-17: Management of Neutropenia and Effectiveness of Sacituzumab Govitecan (SG) in Patients (pts) With Metastatic Triple-Negative Breast Cancer (mTNBC) Treated in Real-World Settings in the United States	Rita Nanda
P1-09-18: Activation of HERV-R is a biomarker of poor prognosis among rural Nigerian women with triple-negative breast cancer.	Faruk Mohammed
P1-09-19: IRENE study: Phase 2 study of oncolytic virus pelareorep and PD-1 inhibitor retifanlimab in metastatic triple negative breast cancer	Mridula George
P1-09-20: Enhancer of zeste homologue 2 (EZH2) inhibition in Triple Negative Breast Cancer (TNBC) attenuates tumor growth in vitro and in vivo altering the tumor immune microenvironment.	Eswar Shankar
P1-09-21: Metabolic Reprogramming in Breast Cancer Brain Metastasis Mouse Model: Insights from Transcriptomic Analysis	Julie Marin
P1-09-22: Mechanistic Insight into DAXX-Modulated Sensitivity to Chemotherapy in Triple Negative Breast Cancer	Clodia Osipo
P1-09-23: Breast cancer-derived miR-4732-3p promotes breast cancer brain metastasis and brain-metastatic tumor microenvironment	Munazza S. Khan
P1-09-24: Cancer cell-derived exosomal miR-20a-5p inhibits CD8+ T-cell function and confers anti-programmed cell death 1 therapy resistance in triple-negative breast cancer	XIANGDONG BAI
P1-09-25: Population Pharmacokinetics (PopPK) and Exposure-Response (E-R) Analyses of Sacituzumab Govitecan (SG) in Japanese Patients (pts) with Metastatic Triple-Negative Breast Cancer (mTNBC) and other Advanced Solid Tumors	Anees M. Dauki
P1-09-26: Genomic analysis of circulating tumor DNA (ctDNA) from patients with triple-negative, HER2-mutant metastatic breast cancer treated with neratinib as monotherapy or in combination with trastuzumab in the SUMMIT trial	Komal Jhaveri
P1-09-27: MELK as a mediator of stemness and metastasis in aggressive subtypes of breast cancer	Breanna McBean

P1-09-28: Sociodemographic Experiences in Treatment (Tx) Patterns and Survival Outcomes in Women With Metastatic Triple-Negative Breast Cancer (mTNBC) in the United States (US): role of disparities	Sara M. Tolaney
P1-09-29: Safety, efficacy and emerging biomarker data from the Phase Ib part of a Phase Ib/II clinical study of nadunolimab in combination with gemcitabine and carboplatin in patients with advanced triple negative breast cancer (TRIFOUR study)	Marta Santisteban Eslava
P1-09-30: Characteristics associated with sacituzumab govitecan response in the real-world setting	Megan Wong
P1-10-01: Overall survival and treatment patterns of incident triple negative breast cancer diagnosed in 2015-2020: single centre study in Poland.	Roman Dubianski
P1-10-03: Real World Effectiveness and Economic Outcomes of First Line CDK4/6 Inhibitors in Combination with AI for HR+/HER2- Metastatic Breast Cancer in a US Medicare Eligible Population	Stella Stergiopoulos
P1-10-04: First results of the WAVES study: Significant increase of patient satisfaction with longer initial consultation duration for breast cancer diagnosis	Nina Ditsch
P1-10-05: Real-World Molecular Profiling After CDK4/6 Inhibition in Advanced Breast Cancer: Analysis of the SOLTI-1903 HOPE Study	Elia Segui
P1-10-06: DETERMINANTS OF SURVIVAL IN MALIGNANT PHYLLODES TUMOR OF THE BREAST: ANALYSIS OF A POOLED DATABASE	Philip Haddad
P1-10-07: PROgress Tracker Breast Cancer Registry: Feasibility of a Longitudinal Peer-Led, National Patient-Reported Outcomes (PRO) Registry	Omar F. Khan
P1-10-08: Characterization of breast cancer subtypes in advanced real-world setting: the GEICAM/2014-03 (RegistEM) study	Isabel Alvarez
P1-10-09: Underestimation in core-needle biopsies of papillary breast lesions: a retrospective cohort from a university center	Renata Puccini
P1-10-10: Outcomes of Abemaciclib Dose Escalation Strategy in High-Risk Early Breast Cancer	Noor Lad

P1-10-11: Preliminary Analysis of Sociodemographic and Clinical Characteristics of Patients with Early Breast Cancer in the Patient-Centered, Real-World EVOLVE Registry	Haley S. Friedler
P1-10-12: Evaluating the Impact of Prosigna® Testing on Adjuvant Chemotherapy Decisions in Early-Stage ER-Positive, HER2-Negative Breast Cancer: A UK Study	Thiraviyam Elumalai
P1-10-13: Real-world outcomes of physician's choice treatment (PCT) for hormone receptor-positive (HR+)/HER2-0 and HER2-low advanced breast cancer (ABC) patients (pts) after endocrine therapy (ET) and CDK4/6 inhibitors (CDK4/6i)	Aleksandra Lacko
P1-10-14: Bridging the gap between real-world studies (RWSs) and randomized controlled trials (RCTs) of 1st-line palbociclib+aromatase inhibitors (P+AI) in hormone receptor-positive(HR+)/HER2-negative(-) metastatic breast cancer (mBC)	Daniele Generali
P1-10-15: Treatment patterns and clinical outcomes according to PD-L1 status in more than 2000 patients with early-stage or metastatic triple-negative breast cancer (eTNBC/mTNBC) treated in the real-world setting: VANESSA study results	Lazar Popovic
P1-10-16: HER 2 + metastatic breast cancer with central nervous involvement, response to Trastuzumab-Deruxtecan in a heavily treated patient: A case report	Ma. Fernanda Noriega-Iriondo
P1-10-17: HER2+ breast cancer diagnosed in the 2nd trimester of pregnancy	Shiliang Zhang
P1-10-19: Hypophysitis and Haziness in HER2: A Case of Breast Cancer with Leptomeningeal Carcinomatosis	Caitlin Sullivan
P1-10-20: Idiopathic granulomatous mastitis with superimposed tuberculosis mastitis	Melissa Rangel
P1-10-21: Intrathecal therapy in invasive lobular carcinoma with non-bulky leptomeningeal disease: case report	Daniel Sobral Filho
P1-10-22: Invasive Ductal Carcinoma of the Breast with Neuroendocrine Differentiation: a Radiologically-Focused Case Report of a Rare Entity	Allen Shieh
P1-10-23: Management of Malignant Adenomyoepithelioma of the Breast	Jacqueline Slobin



P1-10-24: Managing Heterogeneous Metastatic Breast Cancer: A Clinical Case Vignette	Lindsey Ondieki
P1-10-25: Metachronous triple negative breast cancer in a young patient with aggressive presentation of metastatic HER2 positive breast cancer: treatment considerations and management	Alexandra Noveihed
P1-10-26: NSTI of the breast ; a rare and potentially fatal surgical emergency	Melissa Rangel
P1-10-27: NTHL-1 Syndrome in a Breast Cancer Survivor: Malignant Pleural Effusion Unveils Metastatic Colon Adenocarcinoma	Marian Varda
P1-10-28: Pembrolizumab Monotherapy for a Patient with Lynch Syndrome (LS) and Stage 2 Triple-negative Breast Cancer (TNBC): A Clinical Vignette	Sonia Gowda
P1-10-29: Periprosthetic breast implant seroma: a case report and discussion on BIA-ALCL	Dominic Collins
P1-10-30: Pulmonary vein thrombi in metastatic breast cancer: a management dilemma	Kriti Ahuja
P1-11-01: Immune Infiltration Correlates with Transcriptomic Subtypes in Primary ER+ Invasive Lobular Breast Cancer	Fangyuan Chen
P1-11-02: Risk of Recurrence by Nodal Status and High-Risk Features in Patients with HR+, HER2-, Early Breast Cancer: An Analysis of Real-world Data	Sara M. Tolaney
P1-11-03: The Benefits and Burdens of Adjuvant Endocrine Therapy for Older Individuals with Hormone Receptor Positive Breast Cancer	Eileen Rakovitch
P1-11-04: Neoadjuvant Z-endoxifen for Premenopausal Estrogen Receptor (ER)+, Human Epidermal Growth Factor Receptor (HER2)-Breast Cancer (BC): Evaluation of the Pharmacokinetic (PK) Run-in for the EVANGELINE Study.	Matthew Goetz
P1-11-05: Molecular and tumor microenvironment (TME) dynamics and correlations with response of estrogen receptor (ER)-positive breast cancer treated with endocrine therapy (ET), avelumab with or without palbociclib	Phaedon Zavras

P1-11-06: Impact of OncotypeDx Risk Categorization & Receipt of Chemotherapy on Survival Outcomes Among Patients with Small (T1mi/a/b) Node-Negative (NO/NO(i+)/N1mi) Hormone Receptor Positive (HR+) Breast Cancer	Kai Johnson
P1-11-07: Associations between Breast Cancer Index Classifications and MSK-IMPACT Genomic Profiles in HR+/HER2- Breast Cancer	Hong Zhang
P1-11-08: Practice patterns and uptake of adjuvant abemaciclib in high risk localized hormone receptor positive, HER2-negative breast cancer	Sarah Premji
P1-11-09: Clinical Outcomes and the 21-Gene Recurrence Score Assay in Early-Stage Breast Cancer Associated with CHEK2, ATM and PALB2 Germline Pathogenic Variants	Fatma Nihan Akkoc Mustafayev
P1-11-10: Current Endocrine/Systemic Treatment Landscape of ER+ HER2 negative early-stage Breast Cancer: First Data from the RESCUE trial	Johannes Ettl
P1-11-11: Pathological Complete Response and Survival Outcomes of Single Hormone Receptor-Positive/HER2-Negative Breast Cancer after Neoadjuvant Treatment and Further analysis of its Intrinsic Biological Features and Immune Landscape	Lei Ji
P1-11-12: Early-stage HR+/HER2- breast cancer patients under 50 years old with a low-risk identified by the 70-gene signature (MammaPrint™) could benefit from ovarian function suppression: A real-world study in China.	Weijuan Jia
P1-11-13: Development and Validation of a Deep Learning Model for HR+/HER2- Early-stage Breast Cancer Recurrence Prediction (HERPAI) using Conventional Clinical and Pathological Data: A Real-world Study in Chinese Population	Ruixin Pan
P1-11-14: Hormone receptor positive (ER+) HER2+ Lobular Breast Carcinoma: Molecular Response to Perioperative Endocrine Therapy and Clinical Outcomes in the POETIC Trial	Milana Bergamino Sirvén
P1-11-15: Enhancing Risk Stratification in HR+ Early Breast Cancer: A Real-World Evaluation of Oncotype Dx and Prosigna	Nicola Fusco
P1-11-16: Impact of ribociclib dose reduction on efficacy in patients with hormone receptor- positive/human epidermal growth factor receptor 2- negative (HR+/HER2- ) early breast cancer (EBC) in NATALEE	Erika Hamilton
P1-11-17: High Tumor-Infiltrating Lymphocyte Levels Correlate with High MammaPrint® Recurrence Risk in Early-Stage Breast Carcinomas	Zoran Gatalica

P1-11-18: Detrimental effect on survival of neoadjuvant (NACT) versus adjuvant (ACT) chemotherapy in stage II-III hormone receptor-positive & HER2-neg (HR+/HER2-) breast cancer: A propensity score-matched (PSM) analysis of a retrospective patient series.	Armando Orlandi
P1-11-19: Evaluation and Management of Incomplete Ovarian Function Suppression in Premenopausal Breast Cancer Patients Receiving Anti-Hormone Therapy	Elizabeth Weil
P1-11-20: Chemotherapy use in patients with early-stage high-risk ER+/HER2- breast cancer in the United States (US) community setting: A retrospective observational cohort study	Peter Fasching
P1-11-21: Dose Reduction Impacts Persistence on Abemaciclib: A Retrospective Analysis of Real-World Data From the IntegraConnect PrecisionQ De-Identified Database	Vikram Gorantla
P1-11-22: Adjuvant Endocrine Therapy in HR+ Breast Cancer: HCPs Report on Real-World Barriers to Treatment Adherence	Jane Lowe Meisel, MD
P1-11-23: Risk of Disease Recurrence Among Patients with Stage II and III HR-positive, HER2-negative Breast Cancer in Colombia: A Retrospective Cohort Study	Marcela Chalela
P1-11-24: Neoadjuvant Chemotherapy for T3 tumors in the Era of Precision Medicine - Biology is Still King	Christin Collins, Rakhshanda Rahman
P1-11-25: Real-World Data on Adjuvant Abemaciclib in High-Risk Hormone Receptor-Positive Early Breast Cancer: A Retrospective Study	Paola Zagami
P1-11-26: Impact of pre-operative MammaPrint/Blueprint use for final treatment decisions in patients with Stage II/IIIa HR+/HER2- early-stage breast cancer eligible for neoadjuvant chemotherapy: the DETERMIND study.	Antonio Llombart-Cussac
P1-11-27: Comparative Evaluation of Digistain and Oncotype DX in Predicting Metastasis-Free Survival in Early Stage Hormone-Receptor Positive Breast Cancer: A Randomized Study at Charing Cross Hospital	Hemmel Amrania
P1-11-28: Time to Next Treatment of Abemaciclib Plus Endocrine Therapy in Early-Stage High Risk HR+/HER2- Breast Cancer: A Retrospective Analysis of Real-World Data From the IntegraConnect PrecisionQ De-Identified Database	Vikram Gorantla

P1-11-29: Clinical Characteristics and Treatment Persistence in US Patients with HR+/HER2-, Node Positive Early Breast Cancer Treated with Abemaciclib: Real-World Study from First Year After Approval	Hatem Soliman
P1-11-30: The Clinical Utility of NGS-based Multigene Assay in Optimizing Chemotherapy Decisions for Hormone Receptor-Positive Early Breast Cancer: A retrospective study	Min Jung Lee
P1-12-01: HER2 categorical changes after neoadjuvant chemotherapy: A real world data of matched breast cancers with the inclusion of HER2-Low category	Marcelo Antonini
P1-12-02: Real-World Use of Gene Expression Tests in Swedish Breast Cancer Patients: A Multi-Institutional Study of 35 hospitals	Emelie Karlsson
P1-12-03: Clinical Efficacy and Outcomes of Astragalus Polysaccharides (PG2) toward Cancer-related Fatigue of Advanced Breast Cancer Patients	Kun-Ming Rau
P1-12-04: Correlation between Immune-Related Adverse Events (irAE) and Survival Outcomes in Metastatic Breast Cancer Patients Treated with Immune Checkpoint Inhibitors (ICI): a multi-institutional study	Madhuri Chengappa
P1-12-05: Improving Outcomes in Patients With High-risk Breast Cancer: Outcomes and Analysis From an Educational Program on HR+/HER2- Early and Metastatic Breast Cancer	Jerfiz Constanzo
P1-12-06: The Effectiveness of Trastuzumab, Pertuzumab and Docetaxel Combination as a First-Line Treatment of HER2-Positive Metastatic Breast Cancer Patients : A Real-World Evidence in Korea	Min Jeong Kim
P1-12-07: First-line (1L) treatment decision patterns and survival in Peruvian patients (pts) with hormone receptor (HR)-positive HER2-negative advanced breast cancer (ABC)	Guillermo Valencia
P1-12-08: Cyclin-Dependent Kinase 4/6 Inhibitors in Metastatic Breast Cancer and Use of Concomitant Proton Pump Inhibitors: Real-World Experience from a Tertiary Care Center	Maria Alameda-Guijarro
P1-12-09: Real-world prescribing patterns and outcomes of CDK4/6 inhibitors in elderly patients with metastatic HR+/HER2- breast cancer	Xiao-Wei Tan
P1-12-10: Prediction and Survival Analysis of Regional Recurrence in Breast Cancer: Impact of Mode of Detection	Eun Sook Ko

P1-12-11: Individualized Breast Cancer Treatment Strategies: Real-World Insights from the ROSE Study	Nadia Bianco
P1-12-12: Leptomeningeal Metastases in Breast Cancer: Uni-institutional Experience	Daniel Sobral Filho
P1-12-13: Characteristics and Prognosis of Inflammatory Breast Cancer according to Race: A population base study using SEER database	Chai Won Kim
P1-12-14: Characteristics and outcomes of patients with triple negative breast cancer (TNBC) treated with neoadjuvant chemotherapy (NACT) according to race	Leticia Murazawa
P1-12-15: Real-World Assessment of biosimilar Trastuzumab MYL-14010 vs. reference Trastuzumab in HER2-Positive Breast Cancer: Utilization, Efficacy, and Safety in Asian patients	Ming-Chang Tsai
P1-12-16: A Rare Case of Moderate Grade Intraductal Carcinoma in a Young Patient with known Neurofibromatosis 1	Nicholas Gore
P1-12-17: A case of sequential alpelisib and capivasertib in a patient with metastatic breast cancer harboring both a PIK3CA and AKT mutations	Sanjna Rajput
P1-12-18: A case report of paraneoplastic rapidly progressive cerebellar syndrome in a patient with locally recurrent hormone receptor positive (HR+)/HER2- breast cancer	Kelsey Natsuhara
P1-12-19: A case report of successful hair preservation using scalp cooling with doxorubicin and cyclophosphamide during pregnancy	Kelsey Natsuhara
P1-12-20: A rare case of metastatic atypical adenomyoepithelioma of the breast: challenges in systemic treatment.	Anezka Ferrari
P1-12-21: Angiosarcoma of the breast	Alexander Petrovsky
P1-12-22: Breast Implant Associated Squamous Cell Carcinoma (BIA-SCC): A Mayo Clinic Multidisciplinary Approach to Treatment:	Dhauna Karam Prasad

P1-12-23: CASE SERIES OF PATIENTS WITH BREAST CANCER WHO USED HORMONAL IMPLANTS	Rafaella Britto Toledo
P1-12-24: Case Report: Activity of Pembrolizumab in Metastatic Merkel Cell Carcinoma and TNBC	Jessica Liu
P1-12-25: Circulating Tumor DNA (ctDNA) Detection of Local Recurrence in a Patient with Early-Stage Triple Negative Breast Cancer	Samer Alkassis
P1-12-26: Clinical Case Vignette - Molecular PET Imaging to Guide Selection for Endocrine Therapy in Estrogen-Receptor Positive Metastatic Breast Cancer	Wenhui Zhou
P1-12-27: Clinical Case Vignette: Estrogen Receptor Targeting PET Imaging to Monitor Treatment Response to Endocrine Therapy in Lobular Breast Cancer	Wenhui Zhou
P1-12-28: De Novo Metastatic Breast Cancer to the Orbit: A Case Study	Haley Westervelt Mabry
P1-12-29: Extreme response to sacituzumab-govitecan in a patient with metastatic triple-negative breast cancer	Allison Poles
P1-12-30: Genetic Predisposition to Cancer Associated with a Germline Pathogenic BRCA2 Variant: A Clinical Case Report	Zaida Morante